• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重度子痫前期中关于激肽释放酶-激肽系统的血液凝固-纤维蛋白溶解研究。

Studies of blood coagulation-fibrinolysis regarding kallikrein-kinin system in severe preeclampsia.

作者信息

Mutoh S, Kobayashi M, Hirata J, Itoh N, Maki M, Komatsu Y, Yoshida A, Sasa H, Kuroda K, Kikuchi Y

机构信息

Division of Perinatal and Maternal Medicine, Akita University School of Medicine, Japan.

出版信息

Agents Actions Suppl. 1992;38 ( Pt 2):342-9.

PMID:1462840
Abstract

UNLABELLED

In our previous study 1), 2), 3) we reported the changes of coagulation-fibrinolysis, kallikrein-kinin system and kininase in preclampsis. In this study, we tried to obtain systemic information of chronic DIC status with regard to kallikrein-kinin system in severe preeclampsia. This systemic information was evaluated in 20 cases of normal gravidas from 28 to 42 weeks of gestation as a control by measuring plasma Thrombin/Antithrombin III complex (TAT), tissue plasminogen activator (tPA) plasminogen activator inhibitor (PAI) complex, active plasminogen inhibitor-1 (active PAI), 2PI plasmin complex (PIC).

RESULTS

The levels of plasma TAT and tPA significantly increased (TAT = 10.9 +/- 8.3 ng/ml n = 24 M +/- SD P < 0.02, tPA = 6.1 +/- 3.2 ng/ml n = 10 M +/- SD P < 0.01), tPA PAI C and active PAI markedly increased (tPA PAI C = 85.07 +/- 50.01 ng/ml n = 24 P < 0.05, active PAI = 407.4 +/- 166.0 ng/ml n = 24 P < 0.205), and PIC and D-dimer = 435.1 +/- 145.2 ng/ml n = 8 M +/- SD P < 0.001) in severe preeclampsia as compared with those of normal values (TAT = 6.1 2.0 ng/ml, tPA = 3.6 +/- 1.5 ng/ml, tPA PAI C = 57.9 +/- 30.8 ng/ml, active PAI = 304.2 +/- 148.6 ng/ml, PIC = 0.49 +/- 0.24 mg/ml, D-dimer = 282.9 +/- 75.3 ng/ml).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

未标注

在我们之前的研究中,我们报道了子痫前期患者凝血 - 纤溶、激肽释放酶 - 激肽系统及激肽酶的变化。在本研究中,我们试图获取重度子痫前期患者激肽释放酶 - 激肽系统慢性弥散性血管内凝血(DIC)状态的系统信息。通过检测血浆凝血酶/抗凝血酶III复合物(TAT)、组织型纤溶酶原激活物(tPA)、纤溶酶原激活物抑制剂(PAI)复合物、活性纤溶酶原抑制剂 -1(活性PAI)、纤溶酶 -α2纤溶酶抑制物复合物(PIC),对20例妊娠28至42周的正常孕妇作为对照进行了该系统信息评估。

结果

与正常值(TAT = 6.1±2.0 ng/ml,tPA = 3.6±1.5 ng/ml,tPA - PAI - C = 57.9±30.8 ng/ml,活性PAI = 304.2±148.6 ng/ml,PIC = 0.49±0.24 mg/ml,D - 二聚体 = 282.9±75.3 ng/ml)相比,重度子痫前期患者血浆TAT和tPA水平显著升高(TAT = 10.9±8.3 ng/ml,n = 24,M±SD,P < 0.02;tPA = 6.1±3.2 ng/ml,n = 10,M±SD,P < 0.01),tPA - PAI - C和活性PAI显著升高(tPA - PAI - C = 85.07±50.01 ng/ml,n = 24,P < 0.05;活性PAI = 407.4±166.0 ng/ml,n = 24,P < 0.205),PIC和D - 二聚体升高(PIC = 435.1±145.2 ng/ml,n = 8,M±SD,P < 0.001)。(摘要截断于250字)

相似文献

1
Studies of blood coagulation-fibrinolysis regarding kallikrein-kinin system in severe preeclampsia.重度子痫前期中关于激肽释放酶-激肽系统的血液凝固-纤维蛋白溶解研究。
Agents Actions Suppl. 1992;38 ( Pt 2):342-9.
2
Studies on blood coagulation-fibrinolysis system regarding kallikrein-kinin system in the utero-placental circulation during normal pregnancy, labor and puerperium.关于正常妊娠、分娩及产褥期子宫胎盘循环中激肽释放酶-激肽系统的凝血-纤溶系统研究。
Agents Actions Suppl. 1992;38 ( Pt 2):320-9.
3
Urinary coagulation-fibrinolysis, kallirein-kinin systems and kininase in cases of preclampsia.
Agents Actions Suppl. 1992;38 ( Pt 2):330-41.
4
[Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].[冠状动脉溶栓治疗引起的止血和纤溶状态的系列变化]
J Cardiol. 1993;23(4):335-41.
5
Coagulation and fibrinolytic parameters in normal pregnancy and in pregnancy complicated by intrauterine growth retardation.正常妊娠及合并胎儿宫内生长受限妊娠的凝血和纤溶参数
Am J Perinatol. 1998 Feb;15(2):81-5. doi: 10.1055/s-2007-993903.
6
Activation of the plasma clotting, fibrinolytic, and kinin-kallikrein system in preterm infants with severe idiopathic respiratory distress syndrome.重度特发性呼吸窘迫综合征早产儿血浆凝血、纤维蛋白溶解及激肽-激肽释放酶系统的激活
Pediatr Res. 1994 Nov;36(5):647-53. doi: 10.1203/00006450-199411000-00020.
7
Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura.弥散性血管内凝血和血栓性血小板减少性紫癜患者血浆中组织型纤溶酶原激活物抑制因子-I(PAI-I)及tPA/PAI-1复合物的水平。
Clin Appl Thromb Hemost. 2001 Jul;7(3):229-33. doi: 10.1177/107602960100700309.
8
Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy.孕前、孕期及产后血液中纤溶酶原激活剂及其抑制剂的浓度。
Eur J Obstet Gynecol Reprod Biol. 2006 Sep-Oct;128(1-2):22-8. doi: 10.1016/j.ejogrb.2006.02.004. Epub 2006 Apr 11.
9
Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly.成年生长激素缺乏症患者和肢端肥大症患者止血和纤维蛋白溶解标志物的改变。
Exp Clin Endocrinol Diabetes. 2000;108(7):486-92. doi: 10.1055/s-2000-8145.
10
Early markers of blood coagulation and fibrinolysis activation in Argentine hemorrhagic fever.阿根廷出血热中凝血和纤维蛋白溶解激活的早期标志物。
Thromb Haemost. 1995 Mar;73(3):368-73.

引用本文的文献

1
The Diagnostic Efficacy of Thrombelastography (TEG) in Patients with Preeclampsia and its Association with Blood Coagulation.血栓弹力图(TEG)在子痫前期患者中的诊断效能及其与凝血的关系
Open Life Sci. 2019 Jul 22;14:335-341. doi: 10.1515/biol-2019-0037. eCollection 2019 Jan.